Drug intelligence / Profile preview

177Lu-NYM032

Development stage: Unknown
Lead developer: Wuxi Nuoyu Pharmaceutical Technology
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-NYM032 is a therapeutic radiopharmaceutical developed by Wuxi Nuoyu Pharmaceutical Technology for the treatment of prostate cancer. It is a radioligand therapy comprising the beta-emitting radioisotope Lutetium-177 (177Lu) complexed with a ligand that specifically targets Prostate-Specific Membrane Antigen (PSMA), a protein highly overexpressed in prostate cancer cells, particularly in metastatic castration-resistant prostate cancer (mCRPC). Upon intravenous administration, the drug binds to PSMA on the surface of tumor cells and is internalized, allowing the Lutetium-177 to deliver localized, high-energy beta radiation that causes double-stranded DNA breaks and subsequent cell death. This targeted approach aims to minimize damage to surrounding healthy tissues while effectively treating disseminated disease.

Other names: [177Lu]Lu-NYM032

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-NYM032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-NYM032.

Explore the full profile